Utilization Patterns of Qsymia (Phentermine/Topiramate)

    Basic Details
    Date Posted
    Tuesday, August 6, 2019
    Status
    Complete
    Medical Product
    phentermine HCl
    phentermine/topiramate
    Qsymia
    topiramate
    Description

    The goal of this request was to estimate the number of incident users of Qsymia (combination product of phentermine and topiramate), phentermine, topiramate, and concomitant phentermine and topiramate in the Sentinel Distributed Database (SDD). Data from September 17, 2012 to April 30, 2017 from 16 Data Partners contributing to the SDD were included in these reports. This request was distributed on August 17, 2017.

    Report 1 characterizes the uptake and utilization of Qsymia, phentermine, and topiramate, including the distribution of days supply, length of treatment episodes, and time to drug initiation.

    Report 2 estimates the number of incident users of these drugs along with concomitant phentermine and topiramate, with additional estimates among individuals with a history of either epilepsy or seizures, with a history of migraines, and with no history of those conditions. 

    Additional Details
    FDA Center
    CDER
    Time Period
    September 17, 2012 - April 30, 2017
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)